Introduction {#s1}
============

Delaying the occurrence of age related-diseases and frailty (disabilities) and thus prolonging healthspan, would substantially increase the quality of life of the ageing population and could help to reduce healthcare costs. Calorie restriction (CR) or pharmacological inhibition of the mTORC1 pathway by rapamycin are considered as potential effective interventions to delay aging and to increase healthspan in different species ([@bib45]). However, for humans CR is a difficult practice to maintain and may have pleiotropic effects depending on genetic constitution, environmental factors and stage of life. Likewise, the long-term use of rapamycin is limited by the risk of side effects, including disturbed glucose homeostasis, impaired wound healing, gastrointestinal discomfort and others ([@bib5]; [@bib24]; [@bib51]; [@bib85]). Therefore, there is a need to investigate alternative targets that are part of the CR/mTORC1 pathway that can be manipulated to reach similar beneficial effects. Our work suggests that the transcription factor C/EBPβ may provide such a target.

C/EBPβ regulates the expression of metabolic genes in liver and adipose tissue ([@bib28]; [@bib71]). From its mRNA, three protein isoforms are synthesized through the usage of different translation initiation sites: two isoforms acting as transcriptional activators, liver-enriched activator protein (LAP) −1 and −2, and a transcriptional inhibitory isoform called liver-enriched inhibitory protein (LIP) ([@bib27]). We showed earlier that translation into LIP depends on a *cis*-regulatory uORF ([Figure 1A](#fig1){ref-type="fig"}) and is stimulated by mTORC1 signalling ([@bib16]; [@bib44]; [@bib93]). Pharmacological or CR-induced inhibition of mTORC1 in mice selectively reduces LIP-protein synthesis and thereby increases the LAP/LIP ratio in different tissues ([@bib93]). Experimental reduction of LIP expression by genetic ablation of the uORF in C/EBPβ^ΔuORF^ knockin mice is associated with a CR-type improved metabolic profile, including enhanced fatty acid oxidation and reduction of steatosis, improved insulin sensitivity and glucose tolerance, and higher adiponectin levels. Notably, these metabolic improvements are achieved without reducing calorie intake ([@bib1]; [@bib93]). Because of the similarities between t﻿h﻿e C/EBPβ^ΔuORF^ mutation and CR, we investigated lifespan and age-associated phenotypes in C/EBPβ^ΔuORF^ mice.

![C/EBPβ LAP/LIP isoform ratio increases upon ageing.\
(**A**) The graph at the left shows that wt C/EBPβ-mRNA is translated into LAP1 and LAP2 through regular translation initiation, while translation into LIP involves a primary translation of the uORF followed by translation re-initiation at the downstream LIP-AUG by post-uORF-translation ribosomes. The graph at the right shows that genetic ablation of the uORF abolishes translation into LIP, but leaves translation into LAP1 and LAP2 unaffected (for detailed description see \[[@bib16]; [@bib93]\]). (**B** and **C**) Immunoblots of liver samples from young (5 months) and old (female 20 months, male 22 months) wt and C/EBPβ^ΔuORF^ (**B**) males and (**C**) females showing LAP and LIP isoform expression. β-actin expression served as loading control. The LAP/LIP isoform ratio as calculated from quantification by chemiluminescence digital imaging of immunoblots is shown at the right (wt males n = 9 young, n = 10 old; C/EBPβ^ΔuORF^ males, n = 11 young, n = 10 old; wt females, n = 9 young, n = 8 old; C/EBPβ^ΔuORF^ females, n = 10 young, n = 10 old). (**D** and **E**) C/EBPβ mRNA levels as determined by quantitative real-time PCR in (**D**) males (wt, n = 11 young, n = 11 old; C/EBPβ^ΔuORF^, n = 11 young, n = 9 old) and in (**E**) females (wt, n = 9 young, n = 11 old; C/EBPβ^ΔuORF^, n = 9 young, n = 11 old). P-values were determined by Student's t-test, \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.](elife-34985-fig1){#fig1}

Here, we show that the C/EBPβ^ΔuORF^ mutation is associated with an increase in lifespan and reduced tumour incidence in female mice. In addition, we show an improvement in a broad spectrum of age-associated phenotypes to varying degrees in males and females.

Results {#s2}
=======

Others showed that LIP levels increase during aging in liver and white adipose tissue (WAT) ([@bib40]; [@bib48]; [@bib79]). Similarly, in our cohorts of wt C57BL/6J mice LIP levels are significantly higher in livers of old (20--22 months) versus young (5 months) mice, resulting in a decrease in the LAP/LIP ratio during ageing ([Figure 1B,C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). In contrast, in C/EBPβ^ΔuORF^ mice LIP levels are low and stay low in old mice. LAP levels in C/EBPβ^ΔuORF^ males and to a lesser extent in females are increased, which is probably due to additional initiation events at the LAP-AUG by ribosomes that normally would have initiated at the uORF ([@bib16]). The *Cebpb*-mRNA levels are comparable at different ages and in the different genotypes ([Figure 1D,E](#fig1){ref-type="fig"}). Similarly, LIP expression is higher in white adipose tissue (WAT) of old female mice (WAT from males is not available) ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Since translation into LIP is stimulated by mTORC1 through phosphorylation of 4E-binding protein (4E-BP) ([@bib93]), we reasoned that the higher LIP levels in aged livers and WAT might correlate with increased mTORC1 signalling with age. While the analysis of mTORC1-downstream phosphorylation of 4E-BP1 a﻿n﻿d p70 ribosomal protein S6 kinase 1 (S6K1) did not reveal a significant difference between young versus old or wt versus C/EBPβ^ΔuORF^ mice in liver ([Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}), 4E-BP1 phosphorylation was significantly higher in old compared to young WAT samples from both wt and C/EBPβ^ΔuORF^ females ([Figure 1---figure supplement 1E,F](#fig1s1){ref-type="fig"}). In contrast phosphorylation of ribosomal S6 protein in WAT was not significantly altered upon ageing. Thus, LIP levels increase with age and this increase is dependent on the uORF in the *Cebpb*-mRNA and seems to correlate with mTORC1/4E-BP1 signalling in WAT but not in the liver.

We hypothesised that the C/EBPβ^ΔuORF^ mutation may have positive effects on healthspan and lifespan based on the CR-like metabolic improvements in C/EBPβ^ΔuORF^ mice ([@bib93]). A lifespan experiment was set up comparing C/EBPβ^ΔuORF^ mice with wt littermates (C57BL/6J) in cohorts of 50 mice of each genotype and gender. The survival curves revealed an increase in median survival of 20.6% (difference in overall survival p=0.0014 log-rank test, n = 50) for the female C/EBPβ^ΔuORF^ mice compared to wt littermates ([Figure 2A](#fig2){ref-type="fig"}). From the 10% longest-lived females, nine out of ten were C/EBPβ^ΔuORF^ mice ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), showing that the maximum lifespan of C/EBPβ^ΔuORF^ females is significantly increased (p=0.0157 Fisher's exact test). If maximum lifespan is determined by the mean survival of the longest-lived 10% of each cohort, C/EBPβ^ΔuORF^ females show an increase of 9.14% (p-value=0.00105 Student's t-test.). For the male cohort, we observed a modest increase in median survival of 5.2%, however, the overall survival was not significantly increased (p=0.4647 log-rank test, n = 50) ([Figure 2B](#fig2){ref-type="fig"}). The increase in median survival of the combined cohort of C/EBPβ^ΔuORF^ mice (males and females) was 10.5% (with a significant increase in overall survival p=0.0323 log-rank test, n = 100) ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"} and [supplementary file 1](#supp1){ref-type="supplementary-material"}). The observed median survival for wt females (623 days) is lower than what most other labs have reported for C57BL/6J females. We reasoned that this was due to a high incidence of ulcerative dermatitis (UD) we observed particularly in our female cohort (females: 19 mice or 38% for wt and 26 mice or 52% for C/EBPβ^ΔuORF^; males: 15 mice or 30% for wt and 10 mice or 20% for C/EBPβ^ΔuORF^). UD is a common and spontaneous condition in mice with a C57BL/6J background that progress to a severity that euthanasia is inevitable ([@bib36]). Therefore, survival curves were also calculated separately for UD-free mice and for mice that were euthanized because of serious UD ([Figure 2C--F](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B,C](#fig2s1){ref-type="fig"} and [supplementary file 1](#supp1){ref-type="supplementary-material"} for complete overview). These data show that median lifespan of UD-free wt females i﻿s in a more normal range (740 days) and that the C/EBPβ^ΔuORF^ mutation results in a significant increase of median survival specifically in females irrespective of the condition of UD. Moreover, the median survival of the C/EBPβ^ΔuORF^ UD-free females (860.5 days) is higher compared to both wt females and wt males (829 days). The survival curves show an increase in early mortality for the male C/EBPβ^ΔuORF^ mice in the complete and UD-free cohorts ([Figure 2B,D](#fig2){ref-type="fig"}). For these cohorts, we performed a daily chi-square test to access differences between wt and C/EBPβ^ΔuORF^ males on each day of the lifespan and found a significant (p\<0.05) reduction in survival only for the UD-free C/EBPβ^ΔuORF^ males spanning the period 582--637 days, including four mortalities ([Figure 2---figure supplement 1D,E](#fig2s1){ref-type="fig"}). Taken together, these data show that a significant lifespan extension can be concluded only for female C/EBPβ^ΔuORF^ mice.

![Increased survival of female C/EBPβ^ΔuORF^ mice.\
Survival curves of (**A**) the complete female cohorts, (**B**) complete male cohorts, (**C**) the UD-free female cohorts, (**D**) UD-free male cohorts, (**E**) female mice with UD and (**F**) male mice with UD with the survival curves of wt or C/EBPβ^ΔuORF^ mice indicated. The increase in median survival (%) of C/EBPβ^ΔuORF^ compared to wt littermates and statistical significance of the increase in the overall survival as determined by the log-rank test is indicated in the figure.](elife-34985-fig2){#fig2}

Aging is the most important risk factor for development of cancer. A reduction in cancer incidence is recurrently observed upon CR, rapamycin-treatment or manipulation of other pathways that increase longevity in several animal models ([@bib3]; [@bib21]; [@bib49]; [@bib58]; [@bib66]; [@bib75]; [@bib82]). Mice in the lifespan cohorts that died or were sacrificed according to humane endpoint criteria underwent necropsy and tumours were analysed by a board certified veterinary pathologists of the Dutch Molecular Pathology Centre (DMPC). The incidence of neoplasms was markedly reduced in female C/EBPβ^ΔuORF^ mice compared to female wt mice (68% - \> 45,8%, p=0.025 Fisher's exact test) ([Figure 3A](#fig3){ref-type="fig"}). Furthermore, tumours were detected on necropsy at a higher age in female C/EBPβ^ΔuORF^ mice compared to wt mice indicating a delay in tumour development ([Figure 3C](#fig3){ref-type="fig"}). The increase in median survival of the tumour bearing C/EBPβ^ΔuORF^ females was 25.49% compared to that of tumour bearing wt females (p=0.0217 log-rank test) ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Also the tumour load (number of different tumour types per mouse) and the tumour spread (total number of differently located tumours per mouse irrespective of the tumour type) were lower in female C/EBPβ^ΔuORF^ mice ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). For males no significant reduction in tumour incidence was detected in C/EBPβ^ΔuORF^ mice ([Figure 3B,D](#fig3){ref-type="fig"}). The survival of tumour bearing mice and the tumour load was similar in wt and C/EBPβ^ΔuORF^ males, while the tumour spread seems to be even slightly increased in C/EBPβ^ΔuORF^ male mice ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}). The main tumour types found in female mice were lymphoma, hepatocellular carcinoma and histiocytic sarcoma. The occurrence of all three types was reduced in C/EBPβ^ΔuORF^ females ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). For other tumour types, the single numbers are too small to make a clear statement about a change in frequency. In male mice, hepatocellular carcinoma and histiocytic sarcoma were the most frequent tumour types observed. Although the overall tumour incidence was similar in C/EBPβ^ΔuORF^ and wt males, the frequency of hepatocellular carcinoma was reduced in the C/EBPβ^ΔuORF^ males ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

![Reduced incidence and delayed occurrence of tumours in female C/EBPβ^ΔuORF^ mice.\
(**A**) Tumour incidence of females as determined by pathological examination of neoplasms found upon necropsy of mice from the lifespan cohorts (wt, n = 50; C/EBPβ^ΔuORF^, n = 48). Statistical significance was calculated using Fisher's exact test with \*p\<0.05. (**B**) Tumour incidence of males as determined by pathological examination of neoplasms found upon necropsy (wt, n = 47; C/EBPβ^ΔuORF^, n = 45. (**C**) Tumour occurrence in the female lifespan cohorts upon necropsy is shown for wt (black lines) and C/EBPβ^ΔuORF^ mice (red lines). (**D**) Tumour occurrence in the male lifespan cohorts upon necropsy is shown for wt (black lines) and C/EBPβ^ΔuORF^ mice (blue lines).](elife-34985-fig3){#fig3}

Apart from the reduced tumour incidence and the increase in survival of tumour-bearing C/EBPβ^ΔuORF^ females, also the survival of tumour-free female C/EBPβ^ΔuORF^ mice was significantly extended by 25.13% (p=0.0467 log-rank test) compared to wt tumour-free females ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). This suggests that both the tumour incidence and additional unrelated factors contribute to the increased survival of C/EBPβ^ΔuORF^ females. The observed increase in median lifespan of tumour-free C/EBPβ^ΔuORF^ males of 19.71% does not correlate with a statistically significant increase in the overall survival (p=0.4647 log-rank test) ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). However, the survival curve points to a possible health improvement in the median phase of the male lifespan. Taken together, the C/EBPβ^ΔuORF^ mutation in mice restricting the expression of LIP results in a significant lifespan extension and decreased tumour incidence in females but not in males.

Typically, CR-mediated, genetic or pharmacological suppression of mTORC1 signalling is accompanied by the attenuation of an age-associated decline of health parameters ([@bib43]). We examined the selected health parameters of body weight and composition, glucose tolerance, naïve/memory T-cell ratio, motor coordination and muscle strength in separate ageing cohorts of young (3--5 months) and old (18--20 months for females and 20--22 months for males) mice. In addition, we compared the histological appearance of selected tissues (liver, muscle, pancreas, skin, spleen and bone) between old (20/22 months) wt and C/EBPβ^ΔuORF^ mice. Body weight was significantly increased in all old mice ([Figure 4A,B](#fig4){ref-type="fig"}). The increase for the old female C/EBPβ^ΔuORF^ mice was significantly smaller compared to old wt littermates, while for the males there was no significant difference between the genotypes ([Figure 4A,B](#fig4){ref-type="fig"}). The slightly lower body weight for the young C/EBPβ^ΔuORF^ males was also observed in our previous study ([@bib93]). A similar pattern was observed regarding the fat content that was measured by abdominal computed tomography (CT) analysis ([Figure 4C,D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). The volumes of total fat increased strongly in old mice both in visceral and subcutaneous fat depots ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). Old female C/EBPβ^ΔuORF^ mice accumulated significantly less fat in the visceral and subcutaneous fat depots than wt females, while there was no difference for male mice ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). The lean body mass was slightly lower in old female C/EBPβ^ΔuORF^ mice and increased in male wt mice compared to young mice ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). Thus, female C/EBPβ^ΔuORF^ mice gain less fat upon aging similar to mice under CR or upon prolonged rapamycin treatment ([@bib30]). In contrast, although male C/EBPβ^ΔuORF^ mice had a lower body weight and subcutaneous fat content at a young age compared to wt mice they were not able to maintain this difference during the aging process, which correlates with the lack in lifespan extension. In addition, we found an increase in mRNA expression of the macrophage marker *Cd68* as a measure for age-related macrophage infiltration in visceral WAT of old mice, which was attenuated in female but not in male C/EBPβ^ΔuORF^ mice ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

![Ageing-associated increase in body weight, fat content and glucose tolerance is attenuated in female C/EBPβ^ΔuORF^ mice.\
(**A**) Body weight (**g**) of young (4 months) and old (19 months) female mice (wt, n = 11 young, n = 12 old; C/EBPβ^ΔuORF^, n = 11 young, n = 12 old). (**B**) Body weight of young (4 months) and old (21 months) male mice (wt, n = 12 young and old; C/EBPβ^ΔuORF^, n = 12 young, n = 11 old). (**C**) Body fat content (cm^3^) as determined by CT analysis of young (4 months) and old (19 months) female mice (wt, n = 11 young and old; C/EBPβ^ΔuORF^, n = 9 young, n = 11 old). (**D**) Body fat content of young (4 months) and old (21 months) male mice (wt, n = 12 young and old wt; C/EBPβ^ΔuORF^, n = 11 young, n = 9 old). (**E** and **F**) i.p.-Glucose Tolerance Test (IPGTT) was performed with young (4 months) and old (female 19 months, male 21 months) wt and C/EBPβ^ΔuORF^ (**E**) females and (**F**) males. The area under the curve (AUC) at the right shows the quantification (wt females, n = 9 young, n = 10 old; C/EBPβ^ΔuORF^ females, n = 10 young, n = 11 old; wt males, n = 12 young, n = 11 old; C/EBPβ^ΔuORF^ males, n = 11 young, n = 10 old). P-values were determined by Student's t-test, \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.](elife-34985-fig4){#fig4}

Impaired glucose tolerance is a hallmark of the aging process, which is improved by CR ([@bib7]; [@bib63]). The intraperitoneal glucose tolerance test (IPGTT) showed that glucose clearance, calculated as the area under the curve (AUC), is significantly less efficient in old wt compared to young wt mice ([Figure 4E,F](#fig4){ref-type="fig"}). Old C/EBPβ^ΔuORF^ females and males perform significantly better in the IPGTT test than old wt littermates, which is reflected by the lower AUC value. Therefore, the C/EBPβ^ΔuORF^ mutation protects against age-related decline of glucose tolerance in males and females.

The ageing associated increase in memory/naïve T-cell ratio is a robust indicator for the progression of the immunological ageing progress. At a young age naïve T cells predominate and memory T cells are relatively scarce. Upon ageing the naïve T cell population is strongly reduced with a concomitant increase in the memory T cell population, resulting in an increased ratio of memory to naïve T cells ([@bib35]). The ratio of memory (Cd44high) to naïve (Cd44low/Cd62Lhigh) cytotoxic T (Cd8+) cells or memory (Cd44high) to naïve (Cd44low/Cd62Lhigh) helper T (Cd4+) cells was analysed by flow cytometric analysis. Both increased upon aging in the blood of males and females of both genotypes ([Figure 5A--D](#fig5){ref-type="fig"}). However, in C/EBPβ^ΔuORF^ mice of both genders, this increase was significantly attenuated compared to wt mice ([Figure 5A--D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A--D](#fig5s1){ref-type="fig"}). These data suggest that the C/EBPβ^ΔuORF^ mutation preserves a more juvenile immunological phenotype during ageing.

![Ageing-associated increase of the memory/naïve T-cell ratio is attenuated in C/EBPβ^ΔuORF^ mice.\
The ratio between Cd44^high^ memory T cells and Cd44^low^/Cd62L^high^ naïve T cells in blood is shown for young (5 months) and old (female 20 months, male 22 months) (**A, B**) females and (**C, D**) males for both (**A, C**) Cd8^+^ cytotoxic and (**B, D**) Cd4^+^ helper T cells as was determined by flow cytometry (wt females, n = 10 young, n = 12 old; wt males n = 12 young and old; C/EBPβ^ΔuORF^ females, n = 10 young, n = 12 old; C/EBPβ^ΔuORF^ males, n = 12 young and old). P-values were determined by Student's t-test, \*p\<0.05; \*\*\*p\<0.001.](elife-34985-fig5){#fig5}

Aging is associated with a significant decline in motor coordination and muscle strength ([@bib6]; [@bib25]). In the rotarod test, the time is measured that mice endure on a turning and accelerating rod as an indication for their motor-coordination. As expected, rotarod performance decreased with age both for wt female and male mice ([Figure 6A](#fig6){ref-type="fig"}). Remarkably, rotarod performance was completely preserved in old C/EBPβ^ΔuORF^ females but not in C/EBPβ^ΔuORF^ males. In the beam walking test, the required crossing time and number of paw slips of mice traversing a narrow beam are measured. Old mice needed more time to cross the beam reflecting loss of motor coordination upon ageing ([Figure 6B](#fig6){ref-type="fig"}). The aging-associated increase of the crossing time was less severe in C/EBPβ^ΔuORF^ males and females, although statistically significant only in males ([Figure 6B](#fig6){ref-type="fig"}). Nevertheless, the strong increase in the number of paw slips in old wt mice is almost completely attenuated in C/EBPβ^ΔuORF^ males and females ([Figure 6C](#fig6){ref-type="fig"}). Note that the number of paw slips by young C/EBPβ^ΔuORF^ males is already significantly lower compared to young wt males. During the wire hang test, the time is measured that mice endure hangi﻿n﻿g from an elevated wire which serves as an indication for limb skeletal muscle strength ([@bib11]). Similar to the rotarod test, the decline in wire hang performance that is seen in old wt mice is completely restored for the female but not for the male C/EBPβ^ΔuORF^ mice ([Figure 6D](#fig6){ref-type="fig"}).

![Ageing-associated loss of motor coordination and grip strength is attenuated in C/EBPβ^ΔuORF^ mice.\
(**A**) Rotarod performance (time in sec of stay on the rotarod) of young (4 months) and old (female 19 months, male 21 months) wt and C/EBPβ^ΔuORF^ mice is shown separately for females (left) and males (right) (wt females, n = 11 young, n = 12 old; wt males, n = 12 young and old; C/EBPβ^ΔuORF^ females, n = 11 young, n = 12 old; C/EBPβ^ΔuORF^ males, n = 12 young, n = 11 old). (**B**) The crossing time (sec) of the beam walking test of young and old wt and C/EBPβ^ΔuORF^ mice, and (**C**) the number of mistakes (paw slips) made while crossing the beam is shown separately for females and males (wt females, n = 11 young, n = 12 old; wt males, n = 12 young and old; C/EBPβ^ΔuORF^ females, n = 11 young, n = 12 old; C/EBPβ^ΔuORF^ males, n = 12 young, n = 10 old). (**D**) Grip strength as determined with the wire hang test as hanging time (sec) of young and old wt and C/EBPβ^ΔuORF^ mice for females and males separately. N = 11 for young wt and C/EBPβ^ΔuORF^ females and for old C/EBPβ^ΔuORF^ females and n = 12 for old wt females; n = 11 for young and old wt males; n = 12 for young C/EBPβ^ΔuORF^ males and n = 10 for old C/EBPβ^ΔuORF^ males. P-values were determined by Student's t-test, \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.](elife-34985-fig6){#fig6}

Taken together, these data demonstrate that the decline in motor coordination and muscle strength is less severe and partly abrogated in female C/EBPβ^ΔuORF^ mice. The results for the old male C/EBPβ^ΔuORF^ mice are not that clear since they show an improved performance only in the beam walking test. One possible explanation is that only the beam walking test measures purely motor coordination skills whereas the results from the rotarod and wire hang tests are influenced in addition by muscle strength and endurance. Old C/EBPβ^ΔuORF^ males thus might have maintained their motor coordination upon ageing but still suffer from an ageing-dependent loss of muscle strength.

By histological examination of different tissues, we observed a reduction in some age-related alterations in C/EBPβ^ΔuORF^ mice compared to old wt controls ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). We observed a reduced severity of hepatocellular vacuolation and cytoplasmic nuclear inclusions in male C/EBPβ^ΔuORF^ mice; in the pancreas both male and female C/EBPβ^ΔuORF^ mice showed a reduced occurrence and severity of islet cell hyperplasia; in skeletal muscle the number of regenerating muscle fibres was higher in male C/EBPβ^ΔuORF^ mice; the incidence of dermal inflammation was lower in female C/EBPβ^ΔuORF^ mice. Unexpectedly, a slightly increased level of inflammation was detected in the livers of female C/EBPβ^ΔuORF^ mice. The incidence of other potential age-related pathologies like focal acinar cell atrophy and inflammation in the pancreas, liver polyploidy, spleen lymphoid hyperplasia and extramedullary haematopoiesis, intramuscular adipose tissue infiltration, subcutaneous fat atrophy and bone density were not significantly altered between old wt and C/EBPβ^ΔuORF^ mice. We found slightly reduced plasma IGF-1 levels in old C/EBPβ^ΔuORF^ females compared to old wt females ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). A reduction in circulating IGF-1 levels was also found in mice under CR and is believed to be an important mediator of health- and lifespan extending effects of CR ([@bib10]; [@bib63]). Taken together, our data show that multiple, but not all, ageing-associated alterations are attenuated in C/EBPβ^ΔuORF^ mice, and to different extends in males and females.

Finally, we performed a comparative transcriptome analysis from livers of 5 and 20 months old wt and C/EBPβ^ΔuORF^ female mice ([@bib22]; [@bib23]; [@bib65]). A principal component analysis revealed that there was a clear effect of the genotype on gene expression only in the old mice suggesting that the differences in gene expression between wt and C/EBPβ^ΔuORF^ mice are aging dependent ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This is supported by the finding that in young mice only 42 genes were differentially regulated between wt and C/EBPβ^ΔuORF^ mice (FDR \< 0.01; 24 genes upregulated and 18 genes down-regulated in C/EBPβ^ΔuORF^ mice compared to wt mice) while in old mice we found 152 differentially regulated genes (FDR \< 0.01; 127 genes upregulated and 25 genes downregulated in C/EBPβ^ΔuORF^ mice compared to wt mice). Gene ontology (GO) analysis using the David database ([@bib41]) of the genes upregulated in old C/EBPβ^ΔuORF^ mice in comparison to old wt mice revealed GO terms including 'External side of plasma membrane', 'Positive regulation of T-cell proliferation', and 'immune response' (see [Supplementary file 4](#supp4){ref-type="supplementary-material"} for the complete list of GO-terms) whereas the GO-terms: 'Acute phase' and 'Extracellular space' were significantly downregulated ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). Despite the improved metabolic phenotype of C/EBPβ^ΔuORF^ mice ([@bib93]), the analysis did not reveal GO-terms related to metabolism. We reasoned that metabolic genes might not be detected as differentially regulated because they are subject of expression heterogeneity in old mice. Comparison between the coefficient of variation of individual transcripts between young and old mice revealed that inter-individual variation of gene expression increases with age in both genotypes ([Figure 7A,B](#fig7){ref-type="fig"}) supporting earlier observations made by others ([@bib84]). Direct comparison between old wt and C/EBPβ^ΔuORF^ mice showed that this effect is less pronounced in C/EBPβ^ΔuORF^ mice ([Figure 7C](#fig7){ref-type="fig"}). KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway and GO-term enrichment analysis of the highly variably expressed genes in the aged livers revealed that in wt mice particularly metabolic genes related to fatty acid metabolism and oxidative phosphorylation were affected which was not observed in C/EBPβ^ΔuORF^ mice ([Figure 7D](#fig7){ref-type="fig"} and [supplementary file 6](#supp6){ref-type="supplementary-material"} and [7](#supp7){ref-type="supplementary-material"}). In addition, genes whose de-regulation is connected to ageing-associated diseases like non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Huntington's disease and cancer were affected by high inter-individual variation in expression levels in old wt but not in old C/EBPβ^ΔuORF^ mice ([Figure 7D](#fig7){ref-type="fig"}). On the other hand, genes involved in cell cycle, transcription and RNA biology showed higher inter-individual variation in old C/EBPβ^ΔuORF^ mice compared to wt controls ([Supplementary file 7](#supp7){ref-type="supplementary-material"}). These findings suggest that expression control of metabolic genes and genes involved in ageing-associated diseases stays more robust upon aging in C/EBPβ^ΔuORF^ mice.

![Ageing-associated increase of inter-individual variation of gene expression affects different genes in livers from wt and C/EBPβ^ΔuORF^ mice.\
(**A--C**) Inter-individual variability of liver transcripts compared between (**A**) young (5 months) versus old (20 months) female wt mice, (**B**) young (5 months) versus old (20 months) C/EBPβ^ΔuORF^ female mice and (**C**) old wt (20 months) versus old C/EBPβ^ΔuORF^ (20 months) female mice (n = 6 for young and old wt and C/EBPβ^ΔuORF^ for A,B,C). Coefficient of variation of transcripts with mean expression \>1 FPM is plotted against the coefficient of variation of the other group as indicated. Dashed red line represents linear regression and is shifted towards the side that shows higher inter-individual variability. (**D**) KEGG pathway enrichment analysis of genes that show increased inter-individual variability in livers from old wt females compared to old C/EBPβΔuORF females (Coefficient of variation of wt genes is more than twice as the coefficient of variation of the same gene in C/EBPβ^ΔuORF^ females) as indicated by the black bars or of genes that show increased inter-individual variability in livers from old C/EBPβ^ΔuORF^ females compared to old wt C/EBPβ^ΔuORF^ females (Coefficient of variation of C/EBPβ^ΔuORF^ genes is more than twice as the coefficient of variation of the same gene in wt females) as indicated by the red bars. The x-axis indicates the p-value. Only pathways that show significant enrichment (FDR \< 0.05) are shown.](elife-34985-fig7){#fig7}

Discussion {#s3}
==========

Taken together, here we show that loss-of-function mutation of a single *cis*-regulatory element - the uORF - in the *Cebpb*-mRNA, which prevents the translation into the transcription factor C/EBPβ-LIP, results in a remarkable juvenile phenotype in aged mice including lower cancer incidence, lower body weight and body fat, better glucose tolerance, lower memory/naïve T cell ratios, and better maintenance of motor coordination. However, we observed clear differences between males and females, with only females showing improvements for cancer incidence, body weight, fat content, Rotarod- and wire hang test performance. In addition, a significant lifespan extension was only observed for the female C/EBPβ^ΔuORF^ mice.

We do not know what causes the female specific lifespan extension. C/EBP transcription factors are known for their crosstalk with hormone receptors, including estrogen, progesterone and glucocorticoid receptors ([@bib17]; [@bib19]; [@bib33]; [@bib72]; [@bib73]; [@bib76]; [@bib91]). Therefore, obvious differences in hormone receptor regulation between males and females may determine t﻿h﻿e outcome of shifts in LAP/LIP ratios. Notably, the C/EBPβ^ΔuORF^ mutation in males results in higher LAP expression in the liver and therefore 1.5 fold higher LAP/LIP ratios compared to females ([Figure 1B,C](#fig1){ref-type="fig"}). Possibly, higher LAP levels in males have some adverse effects on health and lifespan, which may neutralize the beneficial effects of LIP deficiency. In line with this assumption is that the C/EBPβ^ΔuORF^ males show an increase in early deaths ([Figure 2B,D](#fig2){ref-type="fig"}) that is significant in UD-free males ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}) and is mainly due to early cancer development ([Figure 3D](#fig3){ref-type="fig"}). A similar scenario has been described for short-term treatment with a high dose of rapamycin that failed to extend t﻿h﻿e lifespan of female mice due to frequent development of aggressive haematological cancers ([@bib9]).

The sex-dependent differences we found are intriguing in the light of studies investigating the lifespan extending effects of CR, rapamycin, and mutations in the mTORC1 pathway. For example, CR by 20% has a greater lifespan extending effect in female C57BL/6J or DBA/2J mice compared to males ([@bib63]). In addition, moderate overexpression of the mTORC1-upstream inhibitor TSC1 or deletion of the mTORC1-downstream S6K1 results in lifespan extension only in females ([@bib74]; [@bib90]). Notably, downregulation of LIP under low mTORC1 signalling is dependent on 4E-BP1/2 function and not on inhibition of S6K1 ([@bib93]). Thus, the bias towards female lifespan extension upon reduced mTORC1 signalling seems to be a common feature irrespective of whether the S6K1 or 4E-BP branch is affected. Mutations affecting both mTORC1 and mTORC2 show ambiguous effects; lifespan extension is limited to females in mice heterozygous for mTOR and its cofactor mammalian lethal with Sec 13 protein 8 (mLST8) ([@bib51]), while in a mTOR-hypomorphic mouse model lifespan extension is observed in both males and females ([@bib86]). Similarly, inhibition of mTORC1 with rapamycin results in either a gender biased or a general lifespan extension depending on the study design and rapamycin concentration used. For example, treatment of genetically heterogeneous mice as well as C57BL/6J or C57BL/6Nia mice with a low dose of rapamycin (from 4.7 to 14 ppm) for different time periods has lifespan extending effects that are stronger in females than in males ([@bib32]; [@bib37]; [@bib61]; [@bib62]; [@bib92]). In contrast, treatment with higher concentrations of rapamycin (42 ppm) results in a further increase in lifespan and almost completely alleviates the difference between the sexes ([@bib62]). However, injection of an even higher rapamycin dose (8 mg/kg/day, corresponding to 378 ppm dietary rapamycin) extended lifespan only in males and not in females with serious side effects in females as mentioned above ([@bib9]). These data indicate that rapamycin treatment with low and probably sub-optimal doses creates differences between sexes ([@bib46]). Although the mechanisms behind these sex-dependent differences are not known, our study suggests that mTORC1-LIP regulation may be involved. Possibly, lifespan-extending pathways downstream of mTORC1 are differentially affected by different rapamycin concentrations, and in a gender dependent way. Providing LIP expression is downregulated by low concentrations of rapamycin the female-biased effect on lifespan might be determined predominantly by low LIP levels as well as by the regulation of other highly sensitive targets like for example S6K1 that similarly shows female-specific effects ([@bib74]). At higher rapamycin doses, additional pathways might be engaged from which both males and females benefit. Finally, at too high rapamycin concentrations additional adverse (gender specific) effects might counteract the beneficial effects of rapamycin. Therefore, further research on both positive and negative events downstream of mTORC1 is required to be able to tailor treatment and to minimalize side effects.

Also in mouse strains with alterations in other pathways like the somatotropic axis lifespan extension is often, but not always, more pronounced in females ([@bib13]). Examples of somatotropic-related female biased lifespan extension are Ames dwarf mice that are deficient in growth hormone (GH) and prolactin production ([@bib12]) and insulin-like growth factor 1 (IGF-1) receptor heterozygous mice ([@bib39]). Also in these mouse models the reason for the female-biased lifespan extension is not known.

What contributes to the extended lifespan in the female C/EBPβ^ΔuORF^ mice? Our data indicate that reduced tumour incidence is involved. In line with this is that knockin mice with elevated LIP levels show an increased tumour incidence upon ageing that goes along with reduced survival compared to wt controls ([@bib14]). LIP overexpression can stimulate cell proliferation, migration and transformation in vitro and high LIP levels have been detected in different human tumour tissues ([@bib2]; [@bib4]; [@bib16]; [@bib34]; [@bib44]; [@bib67]; [@bib68]; [@bib88]). Together, these studies suggest an oncogenic role of LIP and that the reduction of LIP in the C/EBPβ^ΔuORF^ mice counteracts tumour development at least partially by cell intrinsic mechanisms. Although the incidence of certain tumours like hepatocellular carcinoma is similarly reduced in male C/EBPβ^ΔuORF^ mice ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) the overall tumour incidence was not different in comparison to the wt males, again indicating gender specific effects of the C/EBPβ^ΔuORF^ mutation. Besides tumour development other parameters contribute to the lifespan extension in female C/EBPβ^ΔuORF^ mice as revealed by the survival curves of the tumour-free female mice ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Notably, the ageing-associated increase in body weight and body fat was attenuated in female but not in male C/EBPβ^ΔuORF^ mice although at younger age also C/EBPβ^ΔuORF^ males show a reduced body weight and fat content ([Figure 4](#fig4){ref-type="fig"}). Our earlier data showed that food intake is not reduced in the C/EBPβ^ΔuORF^ mice ([@bib93]) suggesting that the increase in fat catabolism and other features like the observed higher physical activity cause leanness of the C/EBPβ^ΔuORF^ mice ([@bib93]). In accordance with the difference in fat content, we observed a reduction in macrophage infiltration in white adipose tissue from female but not from male C/EBPβ^ΔuORF^ mice ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Inflammation of the visceral adipose tissue is a common feature of the ageing process and is believed to contribute to insulin resistance and other ageing-associated diseases ([@bib59]). Therefore, reduced inflammation in adipose tissues could contribute to the extended health and lifespan of the female C/EBPβ^ΔuORF^ mice.

Global liver transcriptome analysis revealed an increase in the inter-individual variation of gene expression between individuals from the same genotype. However, there is less variation between old C/EBPβ^ΔuORF^ females than b﻿e﻿t﻿w﻿e﻿e﻿n old wt females. A similar increase in the inter-individual variation of gene expression was also identified by others ([@bib18]; [@bib84]) and might reflect different ageing rates within the same group of individuals. Intriguingly, the inter-individual variation in specific pathways and gene groups is different for C/EBPβ^ΔuORF^ compared to wt mice. Particularly genes connected to metabolic pathways and to ageing-associated diseases showed high expression heterogeneity in old wt but not in old C/EBPβ^ΔuORF^ females. Whether the increased inter-individual variation of metabolic transcripts in old wt mice is a direct effect of the observed increase of the inhibitory-acting LIP isoform or is due to unknown secondary effects has to be clarified in future studies. It is however conceivable that increased transcriptional robustness in the old C/EBPβ^ΔuORF^ mice contributes to the extension in health- and lifespan of the female C/EBPβ^ΔuORF^ mice.

Transcriptome and gene ontology (GO) enrichment analysis in liver revealed some involved mechanisms that could contribute to the youthful and long-lived phenotype of the C/EBPβ^ΔuORF^ females. We found reduced expression of acute phase response genes in livers from old C/EBPβ^ΔuORF^ females. Acute phase response genes are associated with inflammation and their expression in the liver increases upon ageing ([@bib52]). Moreover, expression of acute phase response genes is inhibited by CR or treatment with the CR-mimetic metformin ([@bib56]) suggesting similar protective mechanisms. In addition, we observed the upregulation of several genes connected to lymphocyte biology in the C/EBPβ^ΔuORF^ livers. This fits to the increase in lymphoplasmatic inflammation in the liver of old female C/EBPβ^ΔuORF^ mice ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). It is generally believed that ageing associated lymphocyte infiltration rather promotes the ageing process by increasing inflammatory signals ([@bib77]) that abrogate glucose homeostasis. Nevertheless, recently this view was challenged by showing that hepatic inflammation, involving the activation of IKKβ, can also be beneficial for maintaining glucose homeostasis ([@bib55]). Furthermore, infiltratin﻿g lymphocytes can also contribute to the removal of senescent or pro-tumorigenic cells, thereby acting protective ([@bib47]). Further research is required to find out whether in the case of the female C/EBPβ^ΔuORF^ mice lymphocyte infiltration in the liver has adverse or beneficial effects.

We showed earlier that a *cis*-regulatory uORF in the *Cebpb*-mRNA leader sequence is required for translation into LIP, which is stimulated by mTORC1-4E-BP1 signalling ([@bib15]; [@bib16]; [@bib83]; [@bib93]). Intriguingly, other uORF-dependent translation events are known to be involved in lifespan regulation. In yeast, translation of the *GCN4*-mRNA into the GCN4 transcription factor - a basic leucine zipper (bZIP) domain transcription factor like C/EBPβ - is controlled by four uORFs ([@bib38]). Phosphorylation of the alpha subunit of the eukaryotic initiation factor 2 (eIF2α) by the GCN2 kinase in response to amino acid deprivation or upon other stressors results in global inhibition of translation initiation while GCN4 translation is stimulated due to the skipping of inhibitory uORFs. GCN4 activates genes involved in amino acid biosynthesis and stress response to alleviate nutrient stress ([@bib38]). GCN4 expression is elevated under different conditions that extend either replicative or chronological lifespan in yeast like glucose restriction, inhibition of TOR signalling, depletion of 60S ribosomal subunits or deletion of the arginine transporter canavanine resistance 1 (CAN1) gene and was shown to be at least partially required for the lifespan extending effects of these interventions ([@bib8]; [@bib20]; [@bib50]; [@bib57]; [@bib78]; [@bib80]; [@bib87]). Furthermore, the overexpression of GCN4 is sufficient to extend replicative lifespan in yeast suggesting that GCN4 is a major player in the regulation of yeast lifespan ([@bib64]). In mammals expression of the GCN4 ortholog ATF4 is similarly upregulated in response to stress-induced eIF2α-phosphorylation through skipping of inhibitory uORFs in the *Atf4*-mRNA ([@bib81]). Although an involvement of ATF4 in lifespan regulation in mammals has not been addressed so far, increased expression of AT﻿F4 was found in in livers of long-lived mouse models and upon treatments that extend lifespan and in fibroblasts from slow-ageing Snell dwarf and *Pappa* KO mice ([@bib53]; [@bib54]). In the fibroblasts, increased AT﻿F4 expression was accompanied by an increased stress resistance indicating that AT﻿F4 might play a role also for mammalian lifespan. Notably, C/EBPβ and ATF4 pathways are integrated through heterodimers that bind to composite binding sites ([@bib31]) suggesting that C/EBPβ-ATF4 dimers are involved in health and lifespan regulation in mammals with C/EBPβ-LAP working together with ATF4 in gene activation while C/EBPβ-LIP probably counteracting it. In yeast the deletion of 60S ribosomal subunits was shown to result in a general reduction of occupancy of uORFs indicating uORF skipping although an effect on translation efficiency of the main reading frame was not observed for most of the mRNAs ([@bib64]). Still there might be a subset of uORF containing mRNAs that might be coregulated under low 60S availability and/or other conditions that result in lifespan extension and mediate the lifespan extending effects. In this respect it is intriguing that uORF-mediated translation into the C/EBPβ-LIP isoform is reduced upon knockdown or mutation of the Shwachman-Bodian-Diamond Syndrome (SBDS) protein that is required for 60S ribosomal subunit maturation ([@bib42]). Thus, uORF-mediated translation regulation could be a more general mechanism adjusting gene expression during stress response that might play an important role in lifespan extension.

In summary, reduced signalling through the mTORC1 pathway is thought to mediate many of the beneficial effects of CR or rapamycin treatment ([@bib43]), and both conditions restrict mTORC1-controlled translation into LIP ([@bib16]; [@bib93]). These and other studies firmly place LIP function downstream of mTORC1 at the nexus of nutrient signalling and metabolic gene regulation ([Figure 8](#fig8){ref-type="fig"}). However, upon ageing, LIP expression increases (the LAP/LIP ratio decreases) in the liver and WAT whereas significant changes in mTORC1/4E-BP1 signalling were only detected in WAT ([Figure 1---figure supplement 1C--F](#fig1s1){ref-type="fig"}). Possibly, in the liver other pathways play a role in age-related upregulation of LIP as has been described for the RNA-binding protein CUGBP1 ([@bib48]; [@bib79]).

![Model explaining regulation of LIP under control of mTORC1.\
(**A**) In wt mice C/EBPβ-mRNA translation into LIP is modulated by calorie/nutrient availability through mTORC1 signalling, while expression of LAP is not affected. Together with other mTORC1-controlled pathways (Pathway X and Y) LAP/LIP expression ratio determines healthspan and survival. The different pathways may either be, modulated (C/EBPβ), activated (Pathway X) or inhibited (Pathway Y) by mTORC1 and may have different sensitivities to mTORC1 modulators (e.g. rapamycin or nutrients), creating diversity in response (e.g. based on gender, genetic background or age). In addition LIP is upregulated by mechanisms during aging that are not well understood. (**B**) Genetic ablation of the C/EBPβ-uORF prevents the mTORC1-dependent and/or age-associated upregulation of LIP and results in C/EBPβ-dependent health- and lifespan extension. The C/EBPβ^ΔuORF^ mutation mimics reduced mTORC1 signalling only at the level of LIP expression, leaving mTORC1 control of pathway X and Y unaffected.](elife-34985-fig8){#fig8}

Experimental reduction of the transcription factor C/EBPβ-LIP in mice recapitulates many of the effects of CR or treatment with rapamycin, including the reduced cancer incidence and the generally more pronounced extension of lifespan in females. We have developed a high-throughput screening strategy that allows for discovery of small molecular compounds that suppress the translation into LIP ([@bib89]). The identification of such compounds or conditions that reduce LIP translation may reveal new ways of CR-mimetic-based therapeutic strategies beyond those using mTORC1 inhibition.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                                                           Source or reference                                  Identifiers           Additional information
  (species) or resource                                                                                                                                                      
  ------------------------- --------------------------------------------------------------------- ---------------------------------------------------- --------------------- --------------------------------------------------------------------------
  Genetic reagent\          C/EBPβ^ΔuORF^                                                         DOI:10.1101/gad.557910 DOI:10.15252/embr.201439837   NA                    mice were further back-crossed to 12 generations into C57BL/6 background
  (mus musculus)                                                                                                                                                             

  Antibody                  CD4-PE-Cy7 conjugated                                                 BD Pharmingen                                        Cat\#: 552775         dilution 1:200

  Antibody                  CD62L-FITC conjugated                                                 BD Pharmingen                                        Cat\#: 561917         dilution 1:200

  Antibody                  CD3e-PE conjugated                                                    eBioscience                                          Cat\#: 12--0031       dilution 1:200

  Antibody                  CD8a-eFluor 450 conjugated                                            eBioscience                                          Cat\#: 48--0081       dilution 1:200

  Antibody                  CD44-APC conjugated                                                   eBioscience                                          Cat\#: 17--0441       dilution 1:200

  Antibody                  C/EBPβ (E299) (rabbit monoclonal)                                     Abcam                                                Cat\#: ab32358        dilution 1:1000

  Antibody                  β-actin (rabbit polyclonal)                                           Abcam                                                Cat\#: ab16039        dilution 1:1000

  Antibody                  β-actin (clone C4) (mouse monoclonal)                                 MP Biomedicals                                       Cat\#: 69100          dilution 1:10000

  Antibody                  4E-BP1 (C19) (goat polyclonal)                                        Santa Cruz                                           Cat\#: sc-6024        dilution 1:400

  Antibody                  phospho-4E-BP1 (Thr 37/46) (rabbit polyclonal)                        Cell Signaling                                       Cat\#: 9459           dilution 1:1000

  Antibody                  p70S6K                                                                Cell Signaling                                       Cat\#: 9202           dilution 1:1000

  Antibody                  phospho-p70S6K (Thr389) (108D2) (rabbit monoclonal)                   Cell Signaling                                       Cat\#: 9234           dilution 1:1000

  Antibody                  S6 ribosomal protein (54D2) (mouse monoclonal)                        Cell Signaling                                       Cat\#: 2317           dilution 1:1000

  Antibody                  phospho-S6 ribosomal protein (Ser235/236) (2F9) (rabbit monoclonal)   Cell Signaling                                       Cat\#: 4856           dilution 1:1000

  Antibody                  HRP-linked anti rabbit IgG                                            GE Healthcare                                        Cat\#: NA934          dilution 1:5000

  Antibody                  HRP-linked anti mouse IgG                                             GE Healthcare                                        Cat\#: NA391          dilution 1:5000

  Antibody                  HRP-linked anti goat IgG                                              Santa Cruz                                           Cat\#: sc-2056        dilution 1:5000

  Sequence-based reagent    *Actb* (β-actin) (F)                                                  DOI:10.15252/embr.201439837                          NA                    5'-AGAGGGAA ATCGTGCGTGAC-3\'

  Sequence-based reagent    *Actb* (β-actin) (R)                                                  DOI:10.15252/embr.201439837                          NA                    5\'-CAATAGTG\
                                                                                                                                                                             ATGACCTGGCCGT-3'

  Sequence-based reagent    *Cebpb* (F)                                                           DOI:10.15252/embr.201439837                          NA                    5'-CTGCGGG\
                                                                                                                                                                             GTTGTTGAT\
                                                                                                                                                                             GT-3'

  Sequence-based reagent    *Cebpb* (R)                                                           DOI:10.15252/embr.201439837                          NA                    5'-ATGCTCGA\
                                                                                                                                                                             AACGGAAAA\
                                                                                                                                                                             GGT-3'

  Sequence-based reagent    *Cd68* (F)                                                            this paper                                           NA                    5'-GCCCACC\
                                                                                                                                                                             ACCACCAGT\
                                                                                                                                                                             CACG-3'

  Sequence-based reagent    *Cd68* (R)                                                            this paper                                           NA                    5'-GTGGTCC\
                                                                                                                                                                             AGGGTGAGG\
                                                                                                                                                                             GCCA-3'

  Commercial assay or kit   Mouse IGF specific AssayMax ELISA kit                                 BioCat/Assaypro LLC                                  Cat\#: EMI1001-1-AS   

  Commercial assay or kit   Lightning Plus ECL reagent                                            Perkin Elmer                                         Cat\#: NEL103001EA    

  Commercial assay or kit   Rneasy Plus Mini kit                                                  QIAGEN                                               Cat\#: ID:74134       

  Commercial assay or kit   Transcriptor First Strand cDNA Synthesis kit                          Roche                                                Cat\#: 4379012001     

  Commercial assay or kit   Light Cycler 480 SYBR Green I Master Mix                              Roche                                                Cat\#: 04707516001    

  Commercial assay or kit   TruSeq Sample Preparation V2 Kit                                      Illumina                                             Cat\#: RS-122--2002   

  Commercial assay or kit   Restore Western Blot Stripping buffer                                 Thermo Fisher                                        Cat\#: 21063          

  Commercial assay or kit   RBC-Lysis buffer                                                      BioLegend                                            Cat\#: 420301         

  Commercial assay or kit   QIAzol Lysis re-agent                                                 QIAGEN                                               Cat\#: ID:79306       

  Software, algorithm       GraphPad Prism 7.0                                                    Graphpad Software, La Jolla, CA                                            

  Software, algorithm       DAVID database 6.8                                                    doi:10.1038/nprot.2008.211                                                 

  Software, algorithm       STAR 2.5.2b                                                           doi:10.1093/bioinformatics/bts635                                          

  Software, algorithm       Ensembl gene build 86                                                 <http://www.ensembl.org>                                                   

  Software, algorithm       EdgeR package                                                         doi:10.1152/physiolgenomics.00106.2011                                     

  Software, algorithm       gProfiler tool                                                        doi:10.1093/nar/gkw199                                                     

  Software, algorithm       Image Quant LAS 4000 Mini Imager software                             GE Healthcare                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

C/EBPβ^ΔuORF^ mice described in ([@bib83]) were back-crossed for 12 generations into the C57BL/6J genetic background. Mice were kept at a standard 12 hr light/dark cycle at 22°C in individually ventilated cages (IVC) in a specific-pathogen-free (SPF) animal facility on a standard mouse diet (Harlan Teklad 2916). Mice of the ageing cohort were analysed between 3 and 5 months of age (young) and between 18 and 20 months (old females) or between 20 and 22 months (old males) and were derived from the same breeding pairs as mice used in the lifespan experiment. The body weight of the ageing cohorts was determined before the start of the experimental analysis. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the Thüringer Landesamt für Verbraucherschutz (\#03-005/13) and University of Groningen (\#6996A).

Lifespan experiment {#s4-2}
-------------------

C/EBPβ^ΔuORF^ and wt littermates (50 mice from each genotype and gender) derived from mating between heterozygous males and females were subjected to a lifespan experiment. Mice were housed in groups with maximum five female mice or four male mice per cage (separated in genotypes and genders) and did not participate in other experiments. Mice were checked daily and the lifespan of every mouse (days) was recorded. Mice were euthanized when the condition of the animal was judged as moribund and/or to be incompatible with continued survival due to severe discomfort based on the independent assessment of experienced animal caretakers. All mice that were found dead or were euthanized underwent necropsy with a few exceptions when the grade of decomposition of dead animals prevented further examination (number of mice without necropsy: n = 0 for wt females; n = 2 for C/EBPβ^ΔuORF^ females; n = 3 for wt males and n = 5 for C/EBPβ^ΔuORF^ males. Survival curves were calculated with the Kaplan-Meier method. Statistical significance was determined by the log-rank test using GraphPath Prism 7 software. Maximum lifespan was determined by the number of mice for each genotype that were within the 10% longest-lived mice of the combined (wt and C/EBPβ^ΔuORF^) cohorts. Statistical significance of observed differences was calculated with Fisher's exact test. In addition, the mean lifespan (± SEM) of the 10% longest lived mice within one genotype was compared to the mean lifespan of the 10% longest lived mice of the other genotype, and the statistical significance was calculated with the Student's T-test.

Tumour incidence {#s4-3}
----------------

Suspected tumour tissue found during necropsy of the lifespan cohorts was fixed in 4% paraformaldehyde and Haematoxylin and Eosin stained tissue slices were analysed by experienced board-certified veterinary pathologists of the Dutch Molecular Pathology Centre (Utrecht University) to diagnose the tumour type. Tumour incidence was calculated as percentage of mice with pathologically confirmed tumours in respect to all mice from the same cohort that underwent necropsy. Tumour occurrence was defined as the time of death of an animal in which a pathologically confirmed tumour was found. Tumour load was defined as number of different tumour types found in the same mouse and tumour spread was defined as number of different organs harbouring a tumour within the same mouse irrespective of the tumour type with the exception that in those cases in which different tumour types were found in the same organ a number \>1 was rated.

Motor coordination experiments {#s4-4}
------------------------------

Rotarod test: Mice were habituated to the test situation by placing them on a rotarod (Ugo Basile) with constant rotation (5 rpm) for 5 min at two consecutive days with two trials per mouse per day separated by an interval of 30 min. In the test phase, two trials per mouse were performed with accelerating rotation (2--50 rpm within 4 min) with a maximum trial duration of 5 min in which the time was measured until mice fell off the rod. Beam walking test: Mice were trained by using a beam of 3 cm width and 100 cm in length at two consecutive days (one trial per mouse per day). At the test day, mice had to pass a 1 cm wide beam, 100 cm in length and beam crossing time and number off paw slips upon crossing was measured during three trials per mouse that were separated by an interval of 20 min. To determine the number of mistakes the number of paw slips per trial was counted upon examination of recorded videos. Wire Hang test: To measure limb grip strength mice were placed with their four limbs at a grid with wire diameter of 1 mm at 20 cm over the layer of bedding material, and the hanging time was measured until mice loosened their grip and fell down. Three trials of maximal 60 s per mouse were performed that were separated by an interval of 30 min.

Body composition {#s4-5}
----------------

The body composition was measured using an Aloka LaTheta Laboratory Computed Tomograph LCT-100A (Zinsser Analytic) as described in ([@bib93]). Percentage body fat was calculated in relation to the sum of lean mass and fat mass.

Bone measurements {#s4-6}
-----------------

Bones of the hind legs were freed from soft tissue and fixed in 4% paraformaldehyde. For determination of the bone volume, trabecular thickness, trabecular number and trabecular separation femurs were analysed by micro CT (Skyscan 1176, Bruker) equipped with an X-ray tube (50 kV/500μA). The resolution was 9 μm, rotation step was set at 1°C, and a 0.5 mm aluminium filter was used. For reconstruction of femora, the region of interest was defined 0.45 mm (for trabecular bone) or 4.05 mm (for cortical bone) apart from the distal growth plate into the diaphysis spanning 2.7 mm (for trabecular bone) or 1.8 mm (for cortical bone). Trabecular bone volume/tissue volume (%), trabecular number per μm, trabecular thickness (μm) and trabecular separation (intertrabecular distance, μm) was determined according to guidelines by ASBMR Histomorphometry Nomenclature Committee ([@bib26]).

Glucose tolerance {#s4-7}
-----------------

The intraperitoneal (i.p.) glucose tolerance test (IPGTT) was performed as described in ([@bib93]). Mice without initial increase in blood glucose concentration were excluded from the analysis.

Flow cytometry {#s4-8}
--------------

Blood cells from 300 μl blood were incubated in RBC-Lysis buffer (Biolegend) to lyse the red blood cells. Remaining cells were washed and incubated with a cocktail of fluorochrome-conjugated antibodies (Cd4-PE-Cy7 (\#552775) and Cd62L-FITC (\#561917) from BD Pharmingen; Cd3e-PE (\#12--0031), Cd8a-eFluor 450 (\#48--0081) and Cd44-APC (\#17--0441) from eBioscience.), incubated with propidium iodide for the detection of dead cells and analysed using the FACSCanto II analyser (BD Biosciences). The following T cell subsets were quantified: Cd3^+^, Cd8^+^, Cd44^high^ cytotoxic memory T cells; Cd3^+^, Cd8^+^, Cd44^low^, Cd62L^high^ cytotoxic naïve T cells, Cd3^+^, Cd4^+^, Cd44^high^ helper memory T cells and Cd3^+^, Cd4^+^, Cd44^low^, Cd62L^high^ helper naïve T cells.

Histology {#s4-9}
---------

Tissue pieces were fixed with 4% paraformaldehyde and embedded in paraffin. Sections were stained with Haematoxylin and Eosin (H and E) and agei﻿n﻿g-related pathologies or tumour types were analysed by experienced board-certified veterinary pathologists of the Dutch Molecular Pathology Centre (Utrecht University). Semi-quantification of muscle regeneration was done by counting the number of myofibers with a row of internalized nuclei (\>4) for five 200x fields. Other ageing-associated lesions were scored subjectively, and the severity of the lesions was graded on a scale between 0 and 3 with 0 = absent; 1 = mild; 2 = moderate and 3 = severe.

Immunoblotting and quantification {#s4-10}
---------------------------------

Mouse liver and WAT tissue was homogenized on ice with a glass douncer in RIPA buffer (150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM TRIS pH 8.0 supplemented with protease and phosphatase inhibitors). Liver extracts were sonicated immediately, WAT extracts were incubated for 1 hr on ice, centrifuged for 15 min at 4°C after which the lipid layer was carefully removed using a cotton bud and then sonicated. Equal amounts of total protein were separated by SDS-PAGE, transferred to a PVDF membrane and incubated with the following antibodies: C/EBPβ (E299) from Abcam, β-actin (ab16039) from Abcam or (\# 69100, clone C4) from MP Biomedicals; 4E-BP1 (C-19) from Santa Cruz; phospho-p70S6K (Thr389) (108D2), p70S6K (\#9202), phospho-S6 ribosomal protein (Ser235/236) (2F9), S6 ribosomal protein (54D2), and phospho-4E-BP1 (Thr 37/46) (\#9459) from Cell Signaling Technology and HRP-linked anti rabbit or mouse IgG from GE Healthcare and HRP-linked anti goat IgG from Santa Cruz. Lightning Plus ECL reagent (Perkin Elmer) was used for detection and for re-probing membranes were incubated in Restore Western Blot Stripping buffer (Thermo Fisher). The detection and quantification of protein bands was performed with the Image Quant LAS 4000 Mini Imager (GE Healthcare) using the supplied software.

Quantitative real-time PCR {#s4-11}
--------------------------

Mouse liver or visceral fat tissue was homogenized on ice with a motor driven pellet pestle (Kontes) in the presence of QIAzol reagent (QIAGEN) and total RNA was isolated as described in ([@bib93]). cDNA synthesis was performed from 1 μg of total RNA with the Transcriptor First Strand cDNA Synthesis Kit (Roche) using random hexamer primers. qRT-was performed with the LightCycler 480 SYBR Green I Master mix (Roche) using the following primers: *Actb* (β-actin): 5'-AGA GGG AAA TCG TGC GTG AC-3\' and 5\'-CAA TAG TGA TGA CCT GGC CGT-3'; *Cebpb*: 5'-CTG CGG GGT TGT TGA TGT-3' and 5'-ATG CTC GAA ACG GAA AAG GT-3'; *Cd68*: 5'-GCC CAC CAC CAC CAG TCA CG-3' and 5'- GTG GTC CAG GGT GAG GGC CA-3'.

Enzyme-linked immunosorbent assay (ELISA) {#s4-12}
-----------------------------------------

Plasma was prepared as described in ([@bib93]) and the IGF-1 specific ELISA was performed according to the instructions of the manufacturer (BioCat).

RNA-seq analysis {#s4-13}
----------------

Liver tissue from young (5 months) and old (20 months) wt and C/EBPβ^ΔuORF^ mice (from six individuals per group) was homogenized on ice with a motor-driven pellet pestle (Kontes) in the presence of QIAzol reagent (Qiagen), and total RNA was isolated as described in ([@bib93]). Preparation of the sequencing libraries was performed using the TruSeq Sample Preparation V2 Kit (Illumina) according to the manufacturer's instructions. High-throughput single-end sequencing (65 bp) of the libraries was performed with an Illumina HiSeq 2500 instrument. Reads were aligned and quantified using STAR 2.5.2b ([@bib29]) against primary assembly GRCm38 using Ensembl gene build 86 (<http://www.ensembl.org>). Genes with average expression level below one fragment per million (FPM) were excluded from the analysis. A generalized linear model was used to identify differential gene expression using EdgeR package ([@bib60]; [@bib70]). The library normalization was left at the standard setting (trimmed mean of M-values, TMM). The resulting p-values were corrected for multiple testing using the Benjamini-Hochberg procedure. Data visualization, calculation of CV (coefficient of variation) and statistical tests were conducted using custom R scripts (Processed data and R script available at <http://www.genomes.nl/CEBPB_delta_uORF/> \[[@bib23]\] or <https://github.com/Vityay/CEBPB_delta_uORF> \[([@bib22]\]; copy archived at <https://github.com/elifesciences-publications/CEBPB_delta_uORF>). Gene ontology (GO) analysis was performed using the DAVID database version 6.8 ([@bib41]) with default DAVID database setting with medium stringency and *Mus musculus* background. KEGG pathway analysis was performed using gProfiler tool ([@bib69]). For dataset see ([@bib65]).

Statistical analysis {#s4-14}
--------------------

Biological replication is indicated (n = x). All graphs show average ± standard error of the mean (s.e.m.). The unpaired, two-tailed Student's t-Test was used to calculate statistical significance of results with \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. Significance of the differences in survival curves was analysed using the log-rank test using Prism7 (GraphPad Software) and significance of the difference in maximum lifespan (number of mice from one cohort within the 10% longest lived mice calculated from the combined cohort) and tumour incidence was calculated using the Fisher's exact test with \*p\<0.05. Daily Chi-square test calculations were carried out to examine the significance of parts of the survival curves.
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###### Table 1 Lifespan experiment summary of results.

^1^ Number of animals in the cohort ^2^ Median survival of the cohort (days) ^3^ Increase of the median survival (percent) ^4^ P-value of the increased survival (log-rank test) ^5^ Mean lifespan of the cohort (days) ^6^ Standard error of the mean ^7^ Number of mice in the cohort in the longest-lived decile of the combined cohort (wt and C/EBPβ^ΔuORF^) ^8^ P-value of increased N~max~^7^ (Fisher's exact test).

10.7554/eLife.34985.018

###### Table 2 Tumour spectrum in wt and C/EBPβ^ΔuORF^ mice.

\*incl. lymphoid leukaemia \*\*incl. malignant round cell neoplasms \*\*\*tumour type could not be unequivocally determined due to inadequate quality of the fixed tumour tissue Absolute numbers of mice with the indicated tumour type of tumours found during necropsy for wt and C/EBPβ^ΔuORF^ males and females are shown. Note that the total number of tumours is higher than the number of tumour-bearing mice due to the eventual occurrence of different tumour types in the same mouse.

10.7554/eLife.34985.019

###### Table 3 Occurrence of ageing-associated pathologies in wt and C/EBPβ^ΔuORF^ mice.

Mice were part of the ageing cohort and the age at analysis was 20 months for females and 22 months for males. ^1^ Number of animals showing the pathology (out of the total number of animals analyzed). ^2^ mean grade of the pathology as calculated from the total number of animals analyzed with 0 = absent, 1 = mild, 2 = moderate and 3 = severe. ^3^ Statistical significance of difference found between wt and C/EBPβ^ΔuORF^ mice from the same gender as calculated using the Student's t-test (ns = not significant). ^4^ Mean number of regenerating muscle fibers found in five histological tissue slices per mouse. Note that a lower number is an indication for a more progressed ageing phenotype. ^5^ mean surface area of intramuscular adipose tissue in percent of the total area of analyzed skeletal muscle tissue as calculated from the total number of animals analyzed. ^6^ Trabecular bone parameters (percent bone volume/tissue volume; Trabecular number per mm; trabecular thickness and trabecular separation) measured by micro-CT analysis.

10.7554/eLife.34985.020

###### Table 4 GO-term analysis of genes upregulated in livers of old C/EBPβ^ΔuORF^ mice.

Functional annotation of genes upregulated in livers of old C/EBPβ^ΔuORF^ female mice compared to livers of old wt female mice (FDR \< 0.01; 103 from 127 genes; 24 unknown IDs) using the DAVID database ([@bib41]).

10.7554/eLife.34985.021

###### Table 5 GO-term analysis of genes downregulated in livers of old C/EBPβ^ΔuORF^ mice.

Functional annotation of genes downregulated in livers of old C/EBPβ^ΔuORF^ female mice compared to livers of old wt female mice (FDR \< 0.01; 23 from 25 genes, two unknown IDs) using the DAVID database ([@bib41]).

10.7554/eLife.34985.022

###### Table 6 GO-term analysis of genes showing high inter-individual variation between livers of old wt female mice.

Functional annotation of genes showing a high inter-individual variation between livers from old wt female mice. Coefficient of variation of transcript levels of the corresponding gene in the livers of wt mice is at least twice as big as the coefficient of variation of the transcript levels of the same gene in the livers from C/EBPβ^ΔuORF^ mice; 1386 from 1414 genes, 28 unknown IDs; using the DAVID database ([@bib41]).

10.7554/eLife.34985.023

###### Table 7 GO-term analysis of genes showing high inter-individual variation between livers of old C/EBPβ^ΔuORF^ female mice.

Functional annotation of genes showing a high inter-individual variation between livers from old wt female mice. Coefficient of variation of transcript levels of the corresponding gene in the livers of C/EBPβ^ΔuORF^ mice is at least twice as big as the coefficient of variation of the transcript levels of the same gene in the livers from wt mice; 1354 from 1375 genes, 21 unknown IDs; using the DAVID database ([@bib41]).

10.7554/eLife.34985.024

Data availability {#s7}
-----------------

For transcriptome dataset see: Müller, C., de Jong, T, Guryev, V, Calkhoven, CF. (2018). Transcriptome profiling of liver samples of C/EBPβΔuORF mice. Retrieved from: <https://www.ebi.ac.uk/arrayexpress/>

The following dataset was generated:

Müller Cde Jong TGuryev V and Calkhoven CF2018Transcriptome profiling of liver samples of C/EBPβΔuORF mice<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6435/>Publicly available at the Electron Microscopy Data Bank (accession no. E-MTAB-6435)
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Decision letter

Sonenberg

Nahum

Reviewing Editor

McGill University

Canada

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Reduced expression of C/EBPβ-LIP extends health- and lifespan in mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and James Manley as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Z. David Sharp (Reviewer \#1); Matt Kaeberlein (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors examined the phenotypes of a mouse with a deletion in the uORF of C/EBPβ. They find that female mice live longer and have several attenuated phenotypes of aging.

This is a well-written and important study that convincingly links CR and rapamycin-mediated lifespan extension to C/EBPβ regulation of LAP/LIP.

Essential revisions:

There is a general consensus among the three reviewers that this is an interesting paper and in principle could be suitable for publication in *eLife*. However, two major issues need be addressed prior to publication.

1\) The dose/sex response requires more discussion. With respect to dose, the data from the ITP clearly suggest that males (at least in UMHET3) don\'t see as much benefit from rapamycin at low doses in terms of lifespan, but they \"catch up\" to females at higher doses. Thus, the statement that effects \"are much stronger in females\" is a bit misleading, as the only dose tested starting in mid-life is the low 14 ppm (1X ITP) dose. Bitto et al., by studying transient rapamycin treatment, saw that at the higher dose males but not females showed a lifespan extension. However, at the lower dose tested (9X ITP), both males and females had their lifespans extended, pretty comparably, but with males perhaps getting a little more benefit. Obviously, the mechanisms behind these effects are not completely known (although the current study is highly suggestive), but one possibility is that rapamycin is doing at least two things: affecting LAP/LIP and something else. Perhaps LAP/LIP is more sensitive than pathway \#2 to mTORC1 inhibition and so at lower doses of rapamycin this happens first, which is why females get more of a benefit at lower dose. At higher doses, pathway \#2 is engaged and both males and females get the benefit. These different possible mechanisms should be discussed.

2\) Information about LAP/LIP changes with age would be very useful, and whether it is correlated with changes in mTOR signaling. If the authors can perform this with banked tissue it would be an excellent experiment.

3\) Another issue the relatively short lifespan of the control population of mice. Even excluding the mice that were sacrificed due to ulcerative dermatitis, the control population is borderline short-lived. Interesting both the UD and non-UD females seem to be extended in the female mutant mice and, although with the range of other ageing phenotypes examined, the concerns of the control population are somewhat mitigated.

10.7554/eLife.34985.029

Author response

> Summary:
>
> The authors examined the phenotypes of a mouse with a deletion in the uORF of C/EBPβ. They find that female mice live longer and have several attenuated phenotypes of aging.
>
> This is a well-written and important study that convincingly links CR and rapamycin-mediated lifespan extension to C/EBPβ regulation of LAP/LIP.

The paper now contains separate Results and Discussion sections to improve the flow (Discussion section). The Discussion section has become quite large. We hope that you agree that because of the many different aspects of the study this is justified.

We have addressed all your questions/comments and you will find our replies below.

> Essential revisions:
>
> There is a general consensus among the three reviewers that this is an interesting paper and in principle could be suitable for publication in eLife. However, two major issues need be addressed prior to publication.
>
> 1\) The dose/sex response requires more discussion. With respect to dose, the data from the ITP clearly suggest that males (at least in UMHET3) don\'t see as much benefit from rapamycin at low doses in terms of lifespan, but they \"catch up\" to females at higher doses. Thus, the statement that effects \"are much stronger in females\" is a bit misleading, as the only dose tested starting in mid-life is the low 14 ppm (1X ITP) dose. Bitto et al., by studying transient rapamycin treatment, saw that at the higher dose males but not females showed a lifespan extension. However, at the lower dose tested (9X ITP), both males and females had their lifespans extended, pretty comparably, but with males perhaps getting a little more benefit. Obviously, the mechanisms behind these effects are not completely known (although the current study is highly suggestive), but one possibility is that rapamycin is doing at least two things: affecting LAP/LIP and something else. Perhaps LAP/LIP is more sensitive than pathway \#2 to mTORC1 inhibition and so at lower doses of rapamycin this happens first, which is why females get more of a benefit at lower dose. At higher doses, pathway \#2 is engaged and both males and females get the benefit. These different possible mechanisms should be discussed.

We now discuss these issues in the Discussion session. We also discuss now the possible involvement of C/EBP-hormone receptor regulation as well as possible effects of higher LAP expression in C/EBPβ^ΔuORF^ males (Discussion section).

> 2\) Information about LAP/LIP changes with age would be very useful, and whether it is correlated with changes in mTOR signaling. If the authors can perform this with banked tissue it would be an excellent experiment.

We may have not been clear enough in our description, but the data (as far as we understand the question well) are already in the paper: Figure 1B,C shows immunoblots from livers of young and old mice for both wt and ΔuORF mutation with LAP/LIP ratio quantifications at the right. In old wt mice LAP/LIP ratios decrease through upregulation of LIP as we describe in the Results section. We now added data showing LIP upregulation in WAT of old females (Figure 1---figure supplement 1B). Unfortunately, we lost WAT stored from males during transport to my new institute.

Figure 1---figure supplement 1C-F shows that in liver we did not find significant changes in the mTORC1-downstream P-S6K/S6K or P-4E-BP1/4E-BP1 between young and old mice. In female WAT P-S6/S6 does not change between young and old, but P-4E-BP1/4E-BP1 does increase in old for both wt and C/EBPβ^ΔuORF^. Therefore, the interpretation is not so easy: we cannot relate these changes in LAP/LIP to changes in mTORC1 signalling with age in liver and in WAT only the P-4E-BP1/4E-BP1 is increased but not P-S6/S6. See Discussion section.

> 3\) Another issue the relatively short lifespan of the control population of mice. Even excluding the mice that were sacrificed due to ulcerative dermatitis, the control population is borderline short-lived. Interesting both the UD and non-UD females seem to be extended in the female mutant mice and, although with the range of other ageing phenotypes examined, the concerns of the control population are somewhat mitigated.

We consider that this is a comment(?) without requiring our action.

[^1]: These authors also contributed equally to this work.
